JP Morgan Chase
APGE icon

JP Morgan Chase’s Apogee Therapeutics APGE Stock Holding History

JP Morgan Chase’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.9M Sell
359,250
-751,220
-68% -$67.7M ﹤0.01% 1510
2026
Q1 		$87.4M Sell
1,110,470
-262,596
-19% -$19.1M 0.01% 1055
2025
Q4 		$104M Buy
1,373,066
+235,335
+21% +$14.8M 0.01% 934
2025
Q3 		$45.2M Buy
1,137,731
+12,161
+1% +$464K ﹤0.01% 1472
2025
Q2 		$48.9M Buy
1,125,570
+162,939
+17% +$6.2M ﹤0.01% 1341
2025
Q1 		$36M Buy
962,631
+925,376
+2,484% +$35.8M ﹤0.01% 1501
2024
Q4 		$1.69M Buy
37,255
+7,700
+26% +$393K ﹤0.01% 4282
2024
Q3 		$1.74M Buy
29,555
+1,212
+4% +$58.1K ﹤0.01% 4110
2024
Q2 		$1.12M Buy
28,343
+4,010
+16% +$195K ﹤0.01% 4201
2024
Q1 		$1.62M Buy
24,333
+1,269
+6% +$55.4K ﹤0.01% 4014
2023
Q4 		$644K Buy
23,064
+9,830
+74% +$197K ﹤0.01% 4631
2023
Q3 		$282K Buy
+13,234
New +$292K ﹤0.01% 4836

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase's APGE Position: Q2 2026 in Review

JP Morgan Chase reduced its Apogee Therapeutics (APGE) stake by 68% in Q2 2026, selling an estimated $67.7M and leaving 359,250 shares worth $47.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

JP Morgan Chase first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $104M in Q4 2025. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • JP Morgan Chase held 359,250 shares of Apogee Therapeutics worth $47.9M as of Q2 2026.
  • JP Morgan Chase sold 751,220 Apogee Therapeutics shares in Q2 2026, an estimated $67.7M.
  • Apogee Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1510 holding.
  • JP Morgan Chase first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • JP Morgan Chase's Apogee Therapeutics position peaked at $104M in Q4 2025.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.